Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease

被引:47
作者
Fonseca, VA
机构
[1] Tulane Univ, Hlth Sci Ctr, Dept Med, New Orleans, LA 70112 USA
[2] Tulane Univ, Hlth Sci Ctr, Dept Pharmacol, New Orleans, LA 70112 USA
关键词
D O I
10.1016/S0002-9149(03)00616-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients with diabetes have a greatly increased relative risk of developing cardiovascular disease when compared with patients without diabetes. Much of this risk is related to insulin resistance and is associated with both traditional and nontraditional cardiovascular risk factors. Therapy for diabetes must address these risk factors in an attempt to prevent and adequately treat cardiovascular disease. Pharmacologic therapy directed toward dyslipidemia and hypertension has a,beneficial effect on risk factors and has been shown to decrease cardiovascular events. The effects of insulin and oral hypoglycemic agents on insulin resistance are variable, and their direct effect on cardiovascular disease is less clear. Metformin is the only oral hypoglycemic agent shown to decrease cardiovascular events independent of glycemia. The thiazolidinediones directly improve insulin resistance, decrease plasma insulin concentration, and have the potential to decrease the risk of cardiovascular disease in patients with diabetes. A number of studies have demonstrated that the thiazolidinediones produce changes in several cardiovascular risk factors associated with the insulin resistance syndrome, including lowering blood pressure, correcting diabetic dyslipidemia, improving fibrinolysis, and decreasing carotid artery intima-medial thickness. These agents bind a newly described class of receptors, peroxisome proliferator-activated receptors, which may have implications for atherosclerosis. Although these drugs increase low-density lipoprotein (LDL) cholesterol, they induce a favorable change in the LDL particle size and susceptibility to oxidation. Long-term clinical trials are being conducted to determine the effect that thiazolidinediones have on cardiovascular events in individuals with type 2 diabetes. (C) 2003 by Excerpta Medica, Inc.
引用
收藏
页码:50J / 60J
页数:11
相关论文
共 138 条
[91]   Inhibitory effect of troglitazone on TNF-α-induced expression of monocyte chemoattractant protein-1 (MCP-1) in human endothelial cells [J].
Ohta, MY ;
Nagai, Y ;
Takamura, T ;
Nohara, E ;
Kobayashi, K .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2000, 48 (03) :171-176
[92]   Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists [J].
Olefsky, JM .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (04) :467-472
[93]   Nonhypoglycemic effects of thiazolidinediones [J].
Parulkar, AA ;
Pendergrass, ML ;
Granda-Ayala, R ;
Lee, TR ;
Fonseca, VA .
ANNALS OF INTERNAL MEDICINE, 2001, 134 (01) :61-71
[94]   Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study [J].
Patel, J ;
Anderson, RJ ;
Rappaport, EB .
DIABETES OBESITY & METABOLISM, 1999, 1 (03) :165-172
[95]   C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus [J].
Pradhan, AD ;
Manson, JE ;
Rifai, N ;
Buring, JE ;
Ridker, PM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (03) :327-334
[96]   Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus [J].
Prigeon, RL ;
Kahn, SE ;
Porte, D .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (03) :819-823
[97]  
PRNICE MJ, 2001, DIABETES S2, V50, pA127
[98]   Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease - A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) [J].
Pyorala, K ;
Pedersen, TR ;
Kjekshus, J ;
Faergeman, O ;
Olsson, AG ;
Thorgeirsson, G .
DIABETES CARE, 1997, 20 (04) :614-620
[99]   Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients [J].
Raji, A ;
Seely, EW ;
Bekins, SA ;
Williams, GH ;
Simonson, DC .
DIABETES CARE, 2003, 26 (01) :172-178
[100]   Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with Type II diabetes [J].
Raskin, P ;
Rappaport, EB ;
Cole, ST ;
Yan, Y ;
Patwardhan, R ;
Freed, MI .
DIABETOLOGIA, 2000, 43 (03) :278-284